Mayne Pharma patents expiration
1. Annovera patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765628 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10632066 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10780047 | MAYNE PHARMA | Method of providing birth control |
Feb, 2039
(14 years from now) | |
| US10940157 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10925882 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US10918649 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| US11529308 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any su...
Dosage: RING;VAGINAL
ANNOVERA family patents
2. Bijuva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846649 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9006222 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11793819 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11529360 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8987237 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10675288 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8846648 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114145 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9301920 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11033626 | MAYNE PHARMA | Progesterone formulations having a desirable pk profile |
Nov, 2032
(8 years from now) | |
| US10806740 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8933059 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11103513 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11166963 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993549 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8993548 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10206932 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US8633178 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US9114146 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10052386 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| US11110099 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US11103516 | MAYNE PHARMA | Natural combination hormone replacement formulations and therapies |
Nov, 2032
(8 years from now) | |
| US10639375 | MAYNE PHARMA | Progesterone formulations |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2021 |
Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient
Market Authorisation Date: 28 December, 2021
Treatment: Treatment of menopause symptoms, including vasomotor symptoms
Dosage: CAPSULE;ORAL
BIJUVA family patents
3. Doryx patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(1 year, 4 months ago) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 11, 2016 |
| New Dosing Schedule(D-136) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX family patents
4. Doryx Mpc patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6958161 | MAYNE PHARMA | Modified release coated drug preparation |
Dec, 2022
(1 year, 4 months ago) | |
| US8715724 | MAYNE PHARMA | Tabletting process |
Feb, 2028
(3 years from now) | |
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(10 years from now) | |
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(10 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Apr 11, 2016 |
| New Dosing Schedule(D-136) | Apr 11, 2016 |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE;ORAL
DORYX MPC family patents
5. Fabior patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| US8808716 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 11, 2015 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 11 May, 2012
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM;TOPICAL
FABIOR family patents
6. Imvexxy patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11351182 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10537581 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11246875 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10835487 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US9289382 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11304959 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11497709 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US10806697 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11241445 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Nov, 2032
(8 years from now) | |
| US11116717 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US11065197 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10888516 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10568891 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US10668082 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US11123283 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Jun, 2033
(9 years from now) | |
| US10471072 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Jun, 2033
(9 years from now) | |
| US9180091 | MAYNE PHARMA | Soluble estradiol capsule for vaginal insertion |
Dec, 2033
(9 years from now) | |
| US10258630 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US10398708 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Dec, 2033
(9 years from now) | |
| US11266661 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of a symptom of vulvar and vaginal atrophy; Treatment of dyspareunia; Treatment of moderate to severe dyspareunia
Dosage: INSERT;VAGINAL
IMVEXXY family patents
7. Lexette patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(12 years from now) | |
| US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(12 years from now) | |
|
US10857159 (Pediatric) | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
May, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 18, 2024 |
| New Dosage Form(NDF) | May 24, 2021 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
LEXETTE family patents
8. Nextstellis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7732430 | MAYNE PHARMA | Drug delivery system comprising a tetrahydroxilated estrogen for use in hormonal contraception |
Mar, 2025
(10 months from now) | |
| US11793760 | MAYNE PHARMA | Orodispersible dosage unit containing an estetrol component |
Jun, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 15, 2026 |
Drugs and Companies using DROSPIRENONE; ESTETROL ingredient
NCE-1 date: 15 April, 2025
Market Authorisation Date: 15 April, 2021
Treatment: Use by females of reproductive potential to prevent pregnancy
Dosage: TABLET;ORAL
NEXTSTELLIS family patents
9. Rhofade patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8815929 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Jan, 2024
(3 months ago) | |
| US8420688 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
Aug, 2024
(3 months from now) | |
| US7812049 | MAYNE PHARMA | Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists |
May, 2028
(4 years from now) | |
| US8883838 | MAYNE PHARMA | Pharmaceutical cream compositions and methods of use |
Dec, 2031
(7 years from now) | |
| US9974773 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US11517560 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10751325 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| US10335391 | MAYNE PHARMA | Stabilized oxymetazoline formulations and their uses |
Jun, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 18, 2020 |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 January, 2017
Treatment: Topical treatment of persistent facial erythema associated with rosacea in adults with 1% oxymetazoline hydrochloride cream; Once daily topical treatment of persistent facial erythema associated with ...
Dosage: CREAM;TOPICAL
RHOFADE family patents
10. Sorilux patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629128 | MAYNE PHARMA | Vitamin formulation |
May, 2026
(2 years from now) | |
| US8269128 | MAYNE PHARMA | Vacuum switch tube |
May, 2026
(2 years from now) | |
| US8263580 | MAYNE PHARMA | Vitamin formulation |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 05, 2022 |
| New Dosage Form(NDF) | Oct 06, 2013 |
| New Indication(I-657) | Sep 27, 2015 |
Drugs and Companies using CALCIPOTRIENE ingredient
Market Authorisation Date: 06 October, 2010
Treatment: Use of calcipotriene foam for the topical treatment of plaque psoriasis in patients aged 4 years and older; Use of a calcipotriene containing foam for the treatment of psoriasis
Dosage: AEROSOL, FOAM;TOPICAL
SORILUX family patents
11. Tolsura patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8771739 | MAYNE PHARMA | Pharmaceutical compositions for poorly soluble drugs |
Jul, 2023
(9 months ago) | |
| US9272046 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US8921374 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US10806792 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US10463740 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
| US9713642 | MAYNE PHARMA | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(9 years from now) | |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
TOLSURA family patents